Key Points {#FPar1}
==========

The site of origin of the primary tumour (left vs. right) in metastatic colorectal cancer is linked to better or poorer outcomes and response to therapy, for example, improved survival outcomes have been demonstrated in patients with *RAS* wild-type metastatic colorectal cancer with left-sided tumours receiving first-line panitumumab in combination with FOLFOX (folinic acid, infusional 5-fluorouracil and oxaliplatin)The current analysis involving the combination of panitumumab plus FOLFIRI (folinic acid, infusional 5-fluorouracil and irinotecan) confirms the prognostic effects of primary tumour location in patients receiving this treatment combination, specifically median progression-free survival was longer in patients with left-sided tumoursThe degree to which therapy can shrink a tumour within 8 weeks of treatment initiation predicts survival outcomes. In this analysis, more patients with left- vs. right- sided disease experienced early tumour shrinkage ≥ 30% and progression-free survival was longer in these patients. However, early tumour shrinkage ≥ 30% was associated with improved progression-free survival in patients regardless of primary tumour location

Introduction {#Sec1}
============

Targeted therapies such as inhibitors of the epidermal growth factor receptor (EGFR) are key treatment options for metastatic colorectal cancer (mCRC) \[[@CR1], [@CR2]\]. However, tumour gene mutations in *RAS* are associated with a lack of response to EGFR-targeted agents in mCRC. For example, in a single-arm, open-label phase II study that is the focus of the retrospective analyses presented in this paper (ClinicalTrials.gov identifier: NCT00508404), the combination of the anti-EGFR monoclonal antibody panitumumab and FOLFIRI (folinic acid, infusional 5-fluorouracil and irinotecan) was associated with better clinical efficacy in patients with *KRAS* wild-type (WT) than in those with *KRAS*-mutant mCRC in the first-line setting \[[@CR3], [@CR4]\].

Panitumumab, in combination with FOLFIRI or FOLFOX (folinic acid, infusional 5-fluorouracil and oxaliplatin), is approved by the European Medicines Agency for the first-line treatment of patients with *RAS* WT mCRC \[[@CR5]\]. In 2016, the European Society for Medical Oncology updated their consensus guideline, recommending doublet chemotherapy plus an anti-EGFR antibody as the preferred treatment for patients with *RAS* WT, to achieve a treatment goal of cytoreduction (tumour shrinkage) and conversion to resectable disease \[[@CR1]\]. In line with this recommendation, treatment with anti-EGFR agents in mCRC have been associated with early tumour shrinkage (ETS), an emerging indicator of treatment response \[[@CR6]--[@CR8]\]. Used increasingly in studies of mCRC, ETS along with another newer endpoint, depth of response (DpR), provide information on tumour shrinkage over and above that provided by the more traditional Response Evaluation Criteria in Solid Tumors (RECIST) \[[@CR9], [@CR10]\]. Early tumour shrinkage offers an early indication of sensitivity to treatment, while DpR reveals the maximum tumour shrinkage achieved; both may relate to overall and post-progression survival \[[@CR7], [@CR11]--[@CR13]\]. Early tumour responses also accompany relief from tumour-associated symptoms \[[@CR14]\]. Interestingly, in a recent analysis of the FIRE-3 study, ETS identified subgroups of patients with both *BRAF*- and *RAS*-mutant mCRC who were sensitive to anti-EGFR therapy. Early tumour shrinkage was associated with significantly longer overall survival (OS) in these patients. No predictive value of ETS for OS was observed in patients with *BRAF-* or *RAS-*mutant mCRC receiving vascular endothelial growth factor A inhibition therapy \[[@CR15]\].

Primary tumour location has been identified as a surrogate marker for tumour biology and has a prognostic impact in patients with mCRC. Specifically, patients with left-sided mCRC tumours have a more favourable prognosis than patients with right-sided tumours \[[@CR16]--[@CR20]\]. These two tumour types differ in aetiology, prevalence, molecular signature and microbiome \[[@CR16], [@CR19], [@CR21]\]. Right-sided tumours are less prevalent but generally have a higher disease stage at presentation and more frequently harbour *BRAF* V600 mutations \[[@CR16], [@CR18], [@CR19]\]. In contrast, chromosomal instability, gene amplification of *HER2* and overexpression of EGFR ligands are more common in left- than right-sided tumours \[[@CR19]\].

Recent retrospective analyses of randomised clinical studies suggest that survival outcomes are improved in patients with primary left-sided tumours receiving treatment with an EGFR-targeted agent vs. comparator regimens, both in first and later lines of treatment \[[@CR22]--[@CR26]\]. A pooled analysis of six randomised studies that investigated the prognostic and predictive value of primary tumour location for targeted agents in first- or second-line mCRC treatment confirmed a significant benefit for chemotherapy plus anti-EGFR therapy in patients with left-sided tumours in terms of OS and progression-free survival (PFS), compared with no significant benefit for those with right-sided tumours \[[@CR25]\]. However, numerical increases in overall response rate were observed in both patients with right- and left-sided tumours who received anti-EGFR treatment \[[@CR25]\]. Despite the limitations of retrospective analyses, the data strongly suggest a greater benefit from treatment with chemotherapy plus anti-EGFR agents for patients with left- vs. right-sided *RAS* WT tumours. However, the data also highlight that some patients with right-sided disease may benefit from anti-EGFR treatment where cytoreduction is the goal \[[@CR25]\]. The impact of tumour location has been investigated in retrospective analyses of trials of first-line panitumumab in combination with FOLFOX, and of the anti-EGFR antibody cetuximab plus FOLFIRI \[[@CR22], [@CR25]\]. To confirm that the effects are consistent for the combination of panitumumab plus FOLFIRI, we report here additional exploratory analyses of the first-line trial of panitumumab plus FOLFIRI (ClinicalTrials.gov identifier: NCT00508404). These analyses aim to investigate the effects of primary tumour location on efficacy outcomes, including ETS, in patients with *RAS* WT mCRC. The association between ETS and treatment efficacy with regard to PFS and objective response rate (ORR) will also be explored. Preliminary results from this analysis have been presented in abstract form \[[@CR27]\].

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This is a retrospective analysis of the single-arm, open-label phase II study of first-line panitumumab plus FOLFIRI in patients with mCRC (NCT00508404). Details of this study have been published previously \[[@CR3], [@CR4]\]. In short, first-line panitumumab 6 mg/kg plus FOLFIRI was administered once every 2 weeks until disease progression (PD). The primary study endpoint was ORR, assessed per modified RECIST version 1 \[[@CR28]\]. Other efficacy endpoints included duration of response and PFS. The incidence of resection of metastases was also reported. Only study patients with *RAS* WT mCRC (i.e., with tumours containing no mutations in *KRAS* or *NRAS* exons 2 \[codons 12/13\], 3 \[codons 59/61\] and 4 \[codons 117/146\]) were included in the current analyses.

Analyses According to Primary Tumour Location {#Sec4}
---------------------------------------------

Primary tumour location was determined from free-text surgery descriptions included in case report forms and/or original pathology reports. Primary tumours located in the caecum to transverse colon were defined as right-sided; tumours located from the splenic flexure to rectum were categorised as left-sided. Patient demographics and disease characteristics at baseline were summarised by primary tumour location.

Radiographic images by computer tomography or magnetic resonance imaging were obtained at screening and every 8 weeks ± 1 week until disease progression and the effect of primary tumour location on the following outcomes was analysed: ETS, objective response, DpR, duration of response and resection rate. Early tumour shrinkage was defined as a ≥ 30% reduction in the sum of the longest diameters of measurable target lesions at week 8. Depth of response was the maximum percentage change from baseline to nadir in patients who had shrinkage, or the percentage change at PD in patients with no shrinkage. Depth of response has a zero value for no change, a positive value for tumour reduction and a negative value for tumour growth. Duration of response was calculated from first confirmed response to first occurrence of PD, per modified RECIST version 1. Progression-free survival was calculated from the enrolment date to the date of first observed PD or death as a result of any cause (whichever occurred first). In addition to analyses by primary tumour location, PFS and ORR were also analysed by ETS status. There was no long-term follow-up of OS in this study.

Statistical Analysis {#Sec5}
--------------------

No formal hypothesis testing was planned for this retrospective analysis. All data were summarised descriptively. For continuous endpoints, the median and interquartile range were provided. For discrete data, frequency and percent distributions were presented. Kaplan--Meier estimates and associated 95% confidence intervals (CIs) were calculated for median PFS. Hazard ratios (HRs) and associated 95% CIs were estimated from a Cox proportional hazard model. No adjustments to this model were made.

Results {#Sec6}
=======

Patients {#Sec7}
--------

As previously reported, 154 patients were enrolled in the study and complete *RAS* data were available for 143 patients \[[@CR3], [@CR4]\]. Of these, 69 patients had *RAS* WT mCRC, nine of whom had *BRAF* mutations \[[@CR3], [@CR4]\]. Among the 52 (75%) patients with *RAS* WT for whom the primary tumour location could be determined, 45 (87%) had left-sided tumours and 7 (13%) had right-sided tumours. Tumour location could not be determined in 17 patients as insufficient information was available in either the case report form or the pathology report. Compared with patients with right-sided tumours, more patients with left-sided tumours had *BRAF* WT mCRC, an Eastern Cooperative Oncology Group performance status of 0, liver plus other metastases, and had received prior adjuvant chemotherapy (Table [1](#Tab1){ref-type="table"}).Table 1Baseline patient demographics and disease characteristics by primary tumour locationPrimary tumour locationAll *RAS* WT (*n *= 69)Left (*n *= 45)Right (*n *= 7)Median age (range), years66 (38--77)58 (50--84)65 (38--84)Sex, *n* (%) Male35 (77.8)5 (71.4)55 (79.7) Female10 (22.2)2 (28.6)14 (20.3)*BRAF* status, *n* (%) Mutant4 (8.9)2 (28.6)9 (13.0) WT41 (91.1)5 (71.4)60 (87.0)Site of metastases, *n* (%) Liver + other24 (53.3)2 (28.6)33 (47.8) Liver only13 (28.9)4 (57.1)26 (37.7) Other only8 (17.8)1 (14.3)10 (14.5)ECOG performance status, *n* (%)  025 (55.6)3 (42.9)35 (50.7)  118 (40.0)4 (57.1)31 (44.9)  22 (4.4)0 (0.0)3 (4.3)Prior adjuvant chemotherapy, *n* (%)9 (20.0)0 (0.0)11 (15.9)Primary tumour location status was unknown for 17 of the 69 patients with *RAS* WT*ECOG* Eastern Cooperative Oncology Group, *WT* wild-type

Impact of Primary Tumour Location on Study Drug Exposure and Efficacy Outcomes {#Sec8}
------------------------------------------------------------------------------

More patients with left- vs. right-sided tumours received the study drug for at least 6 months (56% vs. 43%; Table [2](#Tab2){ref-type="table"}). Patients with left-sided tumours also more frequently experienced ETS ≥ 30% compared with those with right-sided tumours (53% vs. 29%; Table [3](#Tab3){ref-type="table"}). Median PFS was 11.2 months and 7.2 months for patients with left- and right-sided tumours, respectively (HR 1.45 \[95% CI 0.56--3.77\]; Fig. [1](#Fig1){ref-type="fig"}). Objective response rate (60% vs. 57%), median duration of response (13.2 \[95% CI 9.3--47.7\] vs. 14.3 \[3.5--17.3\] months), median DpR (61% vs. 60%) and resection rates (any resection: 13% vs. 14%) were similar for patients with left- and right-sided disease (Table [3](#Tab3){ref-type="table"}).Table 2Study drug exposure by primary tumour locationPrimary tumour location^a^All *RAS* WT (*n *= 69)Left (*n *= 45)Right (*n *= 7)Study drug exposure, *n* (%) \< 3 months5 (11.1)2 (28.6)9 (13.0) ≥ 3 to \< 6 months15 (33.3)2 (28.6)23 (33.3) ≥ 6 to \< 9 months13 (28.9)0 (0.0)17 (24.6) ≥ 9 months12 (26.7)3 (42.9)20 (29.0)*WT* wild-type^a^Primary tumour location status was unknown for 17 of the 69 patients with *RAS* WTTable 3Impact of primary tumour location and early tumour shrinkage on outcomePrimary tumour location^a^All *RAS* WT (*n *= 69)Left (*n *= 45)Right (*n* = 7)Objective response, *n* (%)27 (60.0)4 (57.1)41 (59.4)Median DoR (95% CI), months13.2 (9.3--47.7)14.3 (3.5--17.3)13.0 (9.3--15.7)Median DpR (IQR), %61 (33--77)60 (24--87)59 (26--77)Any resection, *n* (%)6 (13.3)1 (14.3)9 (13.0)R0 resection, *n* (%)3 (6.7)1 (14.3)4 (5.8)Median PFS (95% CI), months11.2 (7.6--17.0)7.2 (1.1--19.1)11.2 (7.6--14.8) Prognostic HR^b^ (95% CI), right vs. left1.45 (0.56--3.77)ETS^c^ ≥ 30%, *n* (%)24 (53.3)2 (28.6)32 (46.4) Median PFS (95% CI), months14.8 (7.6--49.5)16.2 (13.3--19.1)14.3 (8.9--19.1) Overall response, *n*/*N* (%)  Complete response1/24 (4.2)01/32 (3.1)  Partial response19/24 (79.2)2/2 (100)27/32 (84.4)  Stable disease4/24 (16.7)04/32 (12.5)  Progressive disease000ETS^c^ \< 30%, *n* (%)20 (44.4)4 (57.1)33 (47.8) Median PFS (95% CI), months9.0 (4.8--17.0)5.6 (2.1--NE)7.8 (5.8--13.2) Overall response, *n*/*N* (%)  Complete response1/20 (5.0)01/33 (3.0)  Partial response5/20 (25.0)2/4 (50.0)10/33 (30.3)  Stable disease11/20 (55.0)1/4 (25.0)18/33 (54.5)  Progressive disease3/20 (15.0)1/4 (25.0)4/33 (12.1)Unadjusted PFS HR^d^ (95% CI), ETS ≥ 30% vs. ETS \< 30%0.53 (0.22--1.29)0.35 (0.03--3.54)0.47 (0.24--0.93)*CI* confidence interval, *DoR* duration of response, *DpR* depth of response, *ETS* early tumour shrinkage, *HR* hazard ratio, *IQR* interquartile range, *NE* not evaluable, *PFS* progression-free survival, *R0* complete resection, *WT* wild-type^a^Primary tumour location status was unknown for 17 of the 69 patients with *RAS* WT^b^HR \> 1 favours left-sided disease^c^Status was unknown for some patients^d^HR \< 1 favours ETS ≥ 30%Fig. 1Impact of primary tumour location on progression-free survival (PFS)

Early tumour shrinkage ≥ 30% was associated with improved PFS irrespective of primary tumour location (left-sided HR 0.53 \[95% CI 0.22--1.29\]; right-sided HR 0.35 \[0.03--3.54\]; Table [3](#Tab3){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). More patients with ETS ≥ 30% experienced a partial response or complete response to treatment compared with patients with ETS \< 30% (Table [3](#Tab3){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). Of those patients with ETS \< 30%, 33% (11/30) of patients later achieved a complete or partial response.Fig. 2Impact of early tumour shrinkage (ETS) on progression-free survival (PFS)Fig. 3Impact of early tumour shrinkage (ETS) on objective response rate: waterfall plot of relative changes in maximum tumour diameter after 8 weeks of treatment, ETS and characterisation of best objective response (*n* = 65). Response evaluation according to modified Response Evaluation Criteria in Solid Tumors version 1 (*mRECIST v.1*). *CR* complete response, *PD* progressive disease, *PR* partial response, *SD* stable disease

Discussion {#Sec9}
==========

We performed a post-hoc exploratory analysis of a single-arm, open-label phase II study of panitumumab plus FOLFIRI as first-line treatment of mCRC to investigate the effects of primary tumour location on additional endpoints. We observed ETS in both left- and right-sided mCRC tumours after treatment with panitumumab plus FOLFIRI, although more patients with left-sided disease experienced ETS. This finding is in line with data from a recent retrospective analysis of data from patients with *RAS* WT who participated in either a phase III study (PRIME) that compared panitumumab plus FOLFOX4 vs. FOLFOX4 alone or a phase II study (PEAK) that compared mFOLFOX6 plus panitumumab or bevacizumab \[[@CR8]\].

Irrespective of tumour location, ETS ≥ 30% was associated with longer PFS in this study (compared with ETS \< 30%). In line with this finding, a higher proportion of patients with left- vs. right-sided disease achieved ETS ≥ 30% and PFS was longer (11.2 vs. 7.2 months) in these patients. These data are aligned with larger analyses suggesting improved survival outcomes are associated with achievement of ETS in patients with *RAS* WT mCRC receiving panitumumab treatment \[[@CR7]\]. In the PRIME study, treatment with first-line panitumumab plus FOLFOX4 compared with FOLFOX4 alone resulted in a significantly higher percentage of patients achieving ETS ≥ 30% at week 8 (59% vs. 38%, *p* \< 0.001) \[[@CR7]\]. Moreover, regardless of treatment arm, ETS was associated with improved PFS and OS \[[@CR7]\]. Relevant data have also been published from the PLANET-TTD study of previously untreated patients with *KRAS* WT mCRC randomised to panitumumab plus FOLFOX4 or panitumumab plus FOLFIRI \[[@CR29]\]. In that study, 68% of patients with *RAS* WT mCRC receiving first-line panitumumab plus FOLFIRI (*n* = 26) had ETS \[[@CR29]\]. Although focused on the peri-operative period in mCRC, median PFS in these patients was numerically higher than in patients with ETS \< 30% (HR ETS ≥ 30% vs. \< 30% \[95% CI\]: 0.6 \[0.2--1.5\], *p* = 0.253). Considering all patients receiving panitumumab plus either FOLFOX or FOLFIRI (*n* = 53), median PFS was significantly longer in patients with ETS ≥ 30% (15 months) than in those with ETS \< 30% (8 months; HR \[95% CI\] 0.5 \[0.2--0.9\], *p *= 0.013) \[[@CR29]\].

We also report here that more patients with ETS ≥ 30% experienced a partial or complete response to treatment compared with patients with ETS \< 30%. However, it is important to note that one third of patients who did not achieve ETS ≥ 30% went on to achieve a partial or complete response. A notable aspect of ETS is the associated symptomatic benefit for patients. In a recent analysis of PRIME, patients with tumour-related symptoms at baseline who achieved ETS ≥ 30% had statistically significant improvements in quality of life prior to discontinuation of first-line treatment compared with patients without ETS \[[@CR14]\]. Forthcoming studies, designed to prospectively measure ETS, will be important to establish the use of this endpoint in mCRC trials.

In the current study, median PFS was significantly longer in patients with left- vs. right-sided tumours. This finding is in line with those from the CRYSTAL, FIRE-3 and CALGB/SWOG 80405 trials in which patients with *RAS* WT mCRC were treated with first-line cetuximab plus FOLFIRI or FOLFIRI \[[@CR20], [@CR23]\], and is also in agreement with a recent retrospective analysis of the PRIME and PEAK studies \[[@CR22]\]. However, in the current study, ORR appeared to be similar regardless of primary tumour location, which differs from recently published data that indicate a higher ORR for left-sided tumours \[[@CR22], [@CR23]\]. In the original analysis of the current study \[[@CR3]\], ORR in patients with *KRAS* WT was similar to that reported in the CRYSTAL study (56% and 59%, respectively) \[[@CR30]\]. In the current analysis, DpR was also similar in left- and right-sided disease; whereas in the PRIME and PEAK studies, DpR was higher in left- vs. right-sided disease overall and with panitumumab treatment \[[@CR8]\]. The discrepancy between these analyses of ORR and DpR could be related to the limited number of right-sided tumours identified in the current analysis.

This study provides further insights into the impact of primary tumour location on outcomes using analysis of additional response measures. However, interpretation of this analysis is restricted by the single-arm design of the study and the limited sample size. The sample size was further reduced by the fact that insufficient information was available in either the case report form or the pathology report to provide primary tumour location data for 25% of patients with *RAS* WT mCRC, which may have impacted on the validity of these analyses. Of note, the subgroup of patients with right-sided disease contained a very small number of patients, preventing definitive conclusions in these patients to be drawn. Furthermore, in line with previous reports \[[@CR31]\], more patients with right-sided disease had *BRAF*-mutated mCRC (29% vs. 9% in patients with left-sided disease). As *BRAF* mutations are associated with poor prognosis in mCRC \[[@CR31]\], this difference may have contributed to the difference in PFS observed between the two groups. However, previous analyses have found that prognosis remains poor in patients with *RAS/BRAF* WT right-sided disease compared with those with *RAS/BRAF* WT left-sided mCRC \[[@CR22]\].

Despite these limitations, our post-hoc study is the first to report data on tumour location in a trial of first-line panitumumab with FOLFIRI, and the findings align with those reported by larger randomised studies, including those of doublet chemotherapies with anti-EGFR monoclonal antibodies, regarding the association between PFS and ETS. The data also support the conclusions from similar analyses with panitumumab in later lines \[[@CR26]\]. It is of interest that in the current study, two out of seven patients with right-sided tumours showed more than a 30% tumour reduction. This suggests that anti-EGFR therapy could be a treatment option in some patients with right-sided tumours. For example, those requiring rapid symptom relief or treatment with the goal of achieving tumour shrinkage to enable secondary resection. This is supported by a retrospective analysis from the European Society for Medical Oncology which, based on data indicating improved ORR with EGFR-targeted treatment in patients with right-sided *RAS* WT tumours, states that doublet chemotherapy plus EGFR antibody remains a therapy option for these patients where cytoreduction is the treatment goal \[[@CR25]\].

Conclusions {#Sec10}
===========

The current analyses of first-line panitumumab plus FOLFIRI in patients with mCRC have confirmed a prognostic effect of primary tumour location. The results presented here are in line with those from larger studies suggesting improved ETS and PFS with anti-EGFR treatment plus doublet chemotherapy in *RAS* WT left-sided mCRC. Irrespective of tumour location, ETS was associated with improved PFS. Although no firm conclusions can be drawn regarding the activity of panitumumab plus FOLFIRI in patients with *RAS* WT right-sided mCRC owing to the small patient numbers, the presence of ETS in these patients may also predict a PFS benefit from continued treatment in this subpopulation. Panitumumab plus FOLFIRI is an effective first-line treatment for patients with left-sided *RAS* WT mCRC and remains an option for a subgroup of patients with right-sided tumours.
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